

# **mirxes**

TO KNOW. TO ACT.

## **TRANSLATOR PROGRAM**

---

Science-backed commercialization engine  
and validator to help companies accelerate  
revenue growth





**mirxes**  
TO KNOW. TO ACT.

# OUR STORY

---



We are a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests.

Our story began in early 2000s when our founders pioneered a highly sensitive, specific and robust detection technology for microRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, we decided to bring our technology from lab to clinic.

In 2014, we spun off from Agency of Science, Technology and Research (A\*STAR) to commercialise our technology and develop accurate multi-cancer early detection solutions and make them readily available and accessible to people who need them.

We believe that the future of healthcare will shift from treating the sick to preventive healthcare. Our science and innovation will continue as we are committed to changing lives by delivering preventive healthcare solutions to all.




## Our Global Footprint

Team of **300+ staff** based in Singapore, US, China, Japan, including **100+ R&D** staff operating clinical trials globally

Venture backed with **US\$130 million** raised from global healthcare specialists & **strategic investors from US, China and Singapore**

**End-to-end R&D and commercial capability** supported by 100,000+ sqft of R&D labs, IVD manufacturing facilities & clinical labs



# MiRXES works with global distinguished scientific and clinical advisors



**Prof Too Heng-Phon**  
Chairman of the Board  
Chief Scientific Advisor

Fellow, Singapore-MIT Alliance  
Professor of Biochemistry,  
Yong Loo Lin School of Medicine, National University of Singapore  
Winner of Singapore President's Technology Award 2021



**Prof Chng Wee Joo**  
Chief Medical Advisor

Group Director, Research Office, NUHS  
Director, National University Cancer Institute  
Deputy Director, Cancer Science Institute of Singapore  
Provost's Chair & Professor, Vice-Dean, Yong Loo Lin School of Medicine, National University of Singapore



**Prof. Frank J. Slack**

Director, Harvard Medical School  
Initiative for RNA Medicine, USA



**Prof. Takahiro Ochiya**

Tokyo Medical University, Japan  
Lead PI, Japanese national miRNA programme



**Prof. Holger Heyn**

Group Leader, Single-Cell Genomics, National Centre for Genomic Analysis (CNAG-CRG), Spain



**Prof. Lam Kong Peng**

Executive Director, Singapore Immunology Network, A\*STAR



**Prof. Yeoh Khay Guan**

Lead PI, Singapore Gastric Cancer Consortium  
Chief Executive, NUHS  
Senior VP (Health Affairs), NUS




**Prof. Tony Mok**

Chairman, Dept of Clinical Oncology, Chinese University of Hong Kong  
Board of Directors, SCO



# HOW WE CAN HELP

---



## Translator Program

- We champion the interest of healthcare community in the areas of science, investment, education, and industrial relations. We facilitate **Multi-Stakeholder partnerships between policy makers, payers, solution providers, and healthcare delivery providers to enable the commercialization and adoption of preventive healthcare solution**
- We serve as an aggregator for global companies to converge and drive preventive health and early intervention. We aim to improve population health outcomes through increasing accessibility to preventive healthcare.

# What Makes Us Different

---

## Science-backed

We are a global biotechnology firm backed by clinicians and scientists at top research and academic institutions worldwide. We operate some of world's most sophisticated laboratories pioneering clinical applications of cutting-edge research in **RNA biomarkers and genomics**.

## Validation

We are a company built by entrepreneurs, investors, and scientists. Our combined industry expertise makes a great commercialization engine and validator. We will work alongside you in **pricing discovery, revenue channel discovery, and market repositioning**.

## Investor-Partner

We don't just invest in capital but also our expertise and network. We work with you to co-generate measurable business results while sharing risks & rewards. We have been through the product development, growth cycles, fund raising, hiring, and more. We know exactly how to **grow and scale a business**.



# Leverage MiRXES' 4D preventive care platform, anchored by our knowledge and expertise

## DISCOVER



### Research & Development Lab

Largest capacity for miRNA quantitative polymerase chain reactions (qPCR) globally with more than 8 million done in 2021. Capability to run population scale clinical cohorts (N>100,000)

Singapore | USA | China

Japan

## DEVELOP



### Manufacturing Facility

Southeast Asia's largest in vitro (IVD) diagnostic manufacturing facility at 1,400m<sup>2</sup>, employing the best in automation and digitalisation with the principle of 'any mix, any volume'

Singapore | China

## DIAGNOSE



### M Diagnostics Clinical Lab

State-of-the-art 600sqm clinical diagnostic laboratory that provides services such as early cancer detection, Next Generation Sequencing (NGS), and genomics profiling

Singapore | China

Philippines | Malaysia | USA  
| Japan | Indonesia |  
Thailand | Vietnam

## DELIVERY



### Early Medical Centre

Equipped with facilities to conduct blood tests and imaging scans, Early brings together **precise, targeted, integrated suite of diagnostic preventive care tools** to the masses.

Singapore

Philippines | Malaysia |  
Vietnam | China

Current  
Locations

Upcoming  
Locations

# Program Benefits


---



**Price discovery and  
revenue channel discovery**



**We are your buyer/adopter.  
Up to \$1,000,000 contract  
revenue and/or benefits in-  
kind to be awarded**



**Expansion in promising SEA  
markets of growth**



**Scientific and clinical  
advisory and mentorship**




**Plug into our multi-  
stakeholder ecosystem of  
investors, policymakers,  
payors, solution providers,  
and healthcare delivery  
providers**



**Workflow optimization and  
strategizing your market  
positioning**

# Program Timeline





## Areas of Interest

- Companies headquartered in **APAC, Europe, and North America**
- All post-revenue stage companies with innovations aimed at improving **PREVENTIVE** healthcare system's quality and efficiency are encouraged to apply.
  1. **diagnostic solution** (in particular but not limited to point-of-care-testing, imaging diagnostic, IVDs)
  2. **complementary health products** (in particular but not limited to supplements)
  3. **health management programs** (in particular but not limited to weight, mental, sports, fertility)
  4. **digital health solution** (in particular but not limited to telehealth, health analytics, remote monitoring)
  5. **healthcare financing solution** (in particular but not limited to insuretech and microfinancing)
  6. **healthcare supply chain** (in particular but not limited to packaging, distribution, last mile delivery)





# OUR PARTNERSHIPS

---

# Early Medical Centre

Located within the thriving ecosystem of healthcare and life sciences companies in Singapore Science Park 1, the Early Medical Centre is **the region's first healthcare innovation centre** that has been intentionally established and designed to deliver a new standard in healthcare experience and **serve as an aggregation hub for diagnostic solutions.**



early Medical Centre @Ascent



## Partnership with Pulse TCM

### Bridge the latest In East & West

Prevent, diagnose, and manage your health concerns with Early's integration of Traditional Chinese Medicine (TCM). TCM uses many different therapies to address concerns like pain, stress or digestive problems.

We combine the latest technology with time-tested techniques to give you clarity in preventive care.

Visit Pulse TCM at Early Medical Centre





Med247

## Partnership with med247

Bringing blood test-based  
cancer screening into the  
Vietnamese home

MiRXES is currently collaborating with Med247 to bring MiRXES' technology for blood test-based cancer screening into the Vietnamese market. Med247 offers a platform for Vietnamese patients to book clinic appointments and access telehealth services via their smartphone. The app offers home prescription delivery and electronic health record requests. Med247 also has its own chain of convenient-care clinics in Vietnam







# GET IN TOUCH WITH US

---



[www.mirxes.com/translator-program](http://www.mirxes.com/translator-program)



Shaw House — 350 Orchard Road  
#17-07/09 Singapore 238868